ASCO GUIDELINES Bundle

Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475444

Contents of this Issue

Navigation

Page 7 of 13

8 Assessment Table 1. Recommended Geriatric Oncology Tools The following tools can provide estimates of risk for chemotherapy toxicity Items CARG toxicity tool: provides estimates for overall risk of grade 3-5 chemotherapy toxicity. 11 items: prior falls (1 or more vs none), hearing problems (deaf to excellent), limitations in walking one block (limited a lot, limited a little, not limited), difficulties with taking meds, interference of social activities by physical health and/or emotional problems (all of the time to none of the time) as well as age, height, weight, gender, cancer type (gastrointestinal vs genitourinary vs other), dosage (standard vs dose reduced), number of chemotherapy agents (mono vs poly), hemoglobin level, and creatinine clearance. CRASH tool; provides estimates separately for risk of grade 3 hematologic and grade 3-4 non-hematologic toxicity Assessment of risk of hematologic toxicity includes: diastolic blood pressure (>72), IADL score (<26), and lactate dehydrogenase (LDH) (>459); Assessment of risk of non-hematologic toxicity includes: Eastern Cooperative Oncology Group (ECOG)-performance status (PS), MMSE (<30), and MNA (<28); chemotherapy intensity is assessed with MAX2 index. The following screening tools have been independently associated with adverse outcomes in older patients with cancer receiving chemotherapy Items G8 8 items covering appetite, weight loss, neuropsychological problems, BMI, number of medications, patient self-rated health, and age; score of ≥14 signifies impairment Derived from the MNA. (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy